Fig. 1 Compromised hBD-2 function in the CF lung promotes chronic

pulmonary infection by the opportunistic pathogen P. aeruginosa Acknowledgments PD0325901 in vivo This project was funded by an Undergraduate Student Research Award from the Natural Sciences and Engineering Research Council of Canada. Dalcin is the guarantor for this article, and takes responsibility for the integrity of the work as a whole. Conflict of interest Dalcin and Dr Ulanova declare no conflict of interest. Compliance with ethics The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, Doramapimod provided the original author(s) and the source are credited. References 1. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest. 1999;103:303–7.PubMedCentralPubMedCrossRef 2. Dodge JA, Morison S, Lewis PA, et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968–95. Arch Dis Child. 1997;77:493–6.PubMedCentralPubMedCrossRef 3. Rommens JM, Lannuzzi MC, Kerem B, et al. Identification

of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059–65.PubMedCrossRef

4. Bobadilla JL, Macek ALK inhibitor M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. Hum Mutat. 2002;19:575–606.PubMedCrossRef 5. Zhou Y, Song K, Painter RG, et al. Cystic fibrosis transmembrane conductance regulatory recruitment to phagosomes in neutrophils. J Innate Immun. 2013;5:219–30.PubMedCrossRef 6. Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981;305:1489–95.PubMedCrossRef 7. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect. 2002;17:47–56.PubMedCrossRef 8. Hoiby N, Frederiksen B. Microbiology of Lumacaftor nmr cystic fibrosis. In: Hodson ME, Geddes DM, editors. Cystic Fibrosis. London: Arnold; 2000, p. 83–107. 9. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91–100.PubMedCrossRef 10. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998;27:93–9.CrossRef 11. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature. 2000;406:959–64.PubMedCrossRef 12. Oliver A, Canton R, Campo P, Baquero F, Blazquez J.